Dr. Mark Bartlett has degrees in Biochemistry and Organic Chemistry from the Australian National University and a Ph.D. in Immunology and Cell Biology from the John Curtin School of Medical Research in Canberra, Australia. In Australia he conducted research on cardiovascular disease with an emphasis on the role of reactive oxygen species and free radicals. He also studied the role of blood platelets in heart disease, and helped publish the first scientific report of a biochemical link between cigarette smoking and atherosclerosis.
Later Dr. Bartlett became interested in autoimmune inflammatory diseases and examined a number of plant-derived substances for their ability to inhibit graft rejection, inhibit cancer metastasis – or spreading – as well as natural products that were able to inhibit autoimmune disease.
Before joining Pharmanex Dr. Bartlett was a visiting scientist at the National Institutes of Health, National Cancer Institute in Bethesda MD where, at the National Cancer Institute, he investigated the interaction of T-cells with the blood vessel wall, and the role of various adhesion molecules that are used by these cells to communicate with one another. He is currently the Vice President of Global Research and Development for Pharmanex.